Introduction {#s1}
============

Human Immunodeficiency Virus type 2 (HIV-2) was first isolated in 1986 [@pone.0066135-Clavel1]--[@pone.0066135-Clavel3]. As compared to the global HIV-1 pandemic, the HIV-2 epidemic has remained essentially confined to West Africa with a limited spread to other regions [@pone.0066135-DeCock1]. In West Africa, between 10--20% of HIV infections are HIV-2 or HIV-1/HIV-2 dual seropositive [@pone.0066135-daSilva1], [@pone.0066135-Heitzinger1] corresponding to 1--2 million people living with this virus in the region [@pone.0066135-Gottlieb1] although prevalence has been waning over the last few decades [@pone.0066135-Heitzinger1].

Compared with HIV-1 infection, HIV-2 infection is characterized by a much longer asymptomatic stage, lower plasma viral load, slower CD4 cell count decline, lower AIDS-related mortality rate [@pone.0066135-DeCock1], [@pone.0066135-Marlink1]--[@pone.0066135-Gottlieb2], lower rates of mother-to-child transmission [@pone.0066135-AdjorloloJohnson1], [@pone.0066135-Burgard1], [@pone.0066135-ODonovan1], genital tract shedding [@pone.0066135-Hawes1] and sexual transmission [@pone.0066135-Kanki1], [@pone.0066135-Gilbert1]. Nonetheless, a significant proportion of HIV-2 infected individual's progress to AIDS and may benefit from antiretroviral therapy (ART) [@pone.0066135-Peterson1].

All antiretrovirals to date have been developed to inhibit HIV-1 replication and many of them are not active against HIV-2. HIV-2 is intrinsically resistant to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the fusion inhibitor, enfurvirtide [@pone.0066135-Parkin1]--[@pone.0066135-Peterson2]. Moreover, only three protease inhibitors (PI) have potent activity against HIV-2: lopinavir, saquinavir and darunavir [@pone.0066135-Peterson2], [@pone.0066135-Gilleece1]. The nucleoside/tide reverse transcriptase inhibitors (NRTIs) appear to be equally potent against HIV-2 as for HIV-1, however different resistance pathways and a lower genetic barrier to resistance make their use problematic [@pone.0066135-Jallow1], [@pone.0066135-Smith1]. The newer antiretroviral classes, the integrase inhibitors (INI) show promising in vitro activity against HIV-2 isolates [@pone.0066135-Garrett1]--[@pone.0066135-Roquebert1]. Preliminary studies among HIV-2 infected patients showed that the INI class drugs (raltegravir and elvitegravir) is an interesting option among HIV-2 naïve patients as well as those who experience therapeutic failure [@pone.0066135-Damond1], but remains to be formally evaluated through clinical trials. Of note, INI are already included in some guidelines for HIV-2 infection [@pone.0066135-Gilleece1].

There is a lack of evidence-based guidelines on the diagnosis, management and ART use for HIV-2 or HIV-1/HIV-2 dual infections [@pone.0066135-Peterson2], [@pone.0066135-Gilleece1], [@pone.0066135-New1], [@pone.0066135-Priseenchargemdicaledespersonnesinfectesparle1] especially in resource-limited settings [@pone.0066135-Peterson2]. The main reasons are that first the efficacy of ART in HIV-2 infection has not been evaluated through randomized clinical trials [@pone.0066135-Gottlieb1], [@pone.0066135-Matheron1] and second observational cohorts generally have had small numbers of patients and shown relatively poor outcome [@pone.0066135-Drylewicz1]--[@pone.0066135-vanderEnde1] although emerging data suggest LPV/r-based regimens have reasonable efficacy [@pone.0066135-Benard1].

Because of these issues, we designed and organized a West African collaborative cohort of HIV-2 infection within the framework of the International epidemiological Database to evaluate AIDS (IeDEA) [@pone.0066135-Egger1]. We collected data on all HIV-2 and HIV-1/HIV-2 dually seropositive patients both ARV-naïve and ARV-treated and followed-up in clinical centres in the IeDEA-WA network in the West Africa region`.` Here, we report the characteristics of HIV-2 and HIV-1/HIV-2 dually seropositive adults in West Africa presenting for care and on ART.

Methods {#s2}
=======

Description of the Cohort {#s2a}
-------------------------

The organization and structure of the Sub-Saharan IeDEA cohorts have been previously described [@pone.0066135-Egger1] and the HIV-2 cohort collaboration is a newly formed network of HIV-2 and dually HIV-1/HIV-2 seropositive patients in West Africa embedded in the IeDEA-West Africa group. A total of 13 clinics (all are located in urban areas), in five countries (Benin, Burkina-Faso, Cote d'Ivoire, Mali, Senegal) are participating ([Figure 1](#pone-0066135-g001){ref-type="fig"} and [Table 1](#pone-0066135-t001){ref-type="table"}). All of the sites have the capacity to measure CD4 cell counts, hematology and chemistries. Only two countries (Senegal and Cote d'Ivoire) had an equipped laboratory for performing HIV-2 plasma viral load measurements [@pone.0066135-RESAPSI1]--[@pone.0066135-RESAPCI1], however they were not routinely performed.

![Geographical location of the clinical centres participating to the IeDEA-WA-HIV-2 cohort.](pone.0066135.g001){#pone-0066135-g001}
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###### Enrollment per clinical center and per country. IeDEA-WA-HIV-2 cohort, as of December 2011.
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                                                HIV-2-infected patients (%)   Dually seropositive patients (%)      Total                  
  -------------------------------------------- ----------------------------- ---------------------------------- ------------- ------------ -------------
  **Benin**                                                                                                                                
  Service de Médecine Interne, CNHU, Cotonou              7 (1.5)                         4 (0.7)                  6 (2.2)      9 (1.9)         26
  **Burkina-Faso**                                                                                                                         
  CHU Yalgado, Ouagadougou                               44 (9.4)                         54 (9.8)                35 (13.0)    66 (14.3)        199
  Hôpital de jour, Bobo-Dioulasso                        38 (8.1)                         41 (7.4)                 1 (0.4)      1 (0.2)         81
  **Côte d'Ivoire, Abidjan**                                                                                                               
  SMIT, CHU Treichville                                 175 (37.2)                       112 (20.3)              100 (37.1)    90 (19.4)        477
  CNTS, Treichville                                      85 (18.1)                        33 (6.0)                18 (6.7)      36 (7.8)        172
  CIRBA, Treichville                                     48 (10.2)                        46 (8.4)                21 (7.8)      31 (6.7)        146
  USAC, Treichville                                       9 (1.9)                         37 (6.7)                 2 (0.7)      15 (3.2)        63
  MTCT-Plus, Yopougon                                    11 (2.3)                         1 (0.2)                  2 (0.7)      6 (1.3)         20
  CePReF, Yopougon                                       44 (9.4)                        113 (20.5)               77 (28.5)    179 (38.7)       413
  **Mali, Bamako**                                                                                                                         
  Hôpital point G                                         1 (0.2)                         17 (3.1)                 2 (0.7)      5 (1.1)         25
  CHUGabriel Touré                                        8 (1.7)                         19 (3.5)                 6 (2.2)      25 (5.4)        58
  **Senegal, Dakar**                                                                                                                       
  SMIT, CHU Fann                                            --                           74 (13.4)                   --            --           74
  TOTAL                                                 470(100.0)                       551(100.0)              270 (100.0)   463(100.0)   1754(100.0)

Schedule of Follow-up {#s2b}
---------------------

ART was provided by the individual national treatment programs according to their individual treatment algorithms. After initiation into care, patients were typically followed every six months, or were seen in between visits for any intercurrent illness. CD4 count were measured every six months.

Data Collection {#s2c}
---------------

Standardized questionnaires capturing the relevant information on HIV-2 care have been developed with an electronic database implemented at the site level. All sites completed retrospectively and then prospectively the specific questionnaires and have entered the data in the unique IeDEA-WA HIV-2 database. The databases from each site are sent every six months to the Regional Centre in Abidjan, Côte d'Ivoire, and Bordeaux, France using compression/encryption software. Data collected include: 1) Baseline demographics: birth date, gender, HIV clinical stage (WHO or CDC stage), ART initiated, clinical assessment, medical history, 2) Follow-up: Clinical assessment (tuberculosis, other diseases/infection, HIV clinical stage, weight, height, medications such as antiretroviral drugs and cotrimoxazole), 3) Biological data: including CD4, haemoglobin, ALAT, ASAT, plasma HIV RNA viral load (when available, and 4) Outcomes: death, loss to follow-up, and transferred out.

Data Management {#s2d}
---------------

Clinical and biological questionnaires are collected and centralized at the IeDEA West Africa, Regional office in the Programme PACCI in Abidjan where they are checked for accuracy and completeness and transfer to the INSERM U897 Epidemiology centre in Bordeaux, France, for statistical analysis and cohort description. The database used for the current manuscript included information recorded at enrolment as well as during follow-up up to December 2011.

Statistical Analysis {#s2e}
--------------------

Continuous variables are described by their median value and interquartile range (IQR); categorical variables are described as percentages. All statistical tests are two-sided, with a type I error of 5%.

Ethical Aspects {#s2f}
---------------

The study was designed and performed in accordance with the Declaration of Helsinki and was approved by the National ethics committee (IRB) from Benin: Comité National d\'Ethique pour la Recherche en Santé, from Burkina-Faso: Comité d\'Ethique pour la Recherche en Santé, from Côte d'Ivoire: Comité National d\'Ethique et de la Recherche, from Mali: Comité National d'Ethique pour la Santé et les Sciences de la vie and from Senegal: Comité National d\'Ethique pour la Recherche en Santé. A waiver of informed consent was granted by the Institutional Review Boards because we used data collected in routine and used by the national program for monitoring HIV programs. The study procedure did not involve any personal contact with the patients.

Results {#s3}
=======

As of December 2011 the cohort has captured baseline and follow-up data from 1,754 (56% female) HIV-2 or dually seropositive patients, of whom 1,014 (57.8%) have initiated ART ([Table 1](#pone-0066135-t001){ref-type="table"}). Overall, 1,021 HIV-2 infected patients (551 on ART) and 733 dually seropositive for HIV-1 and HIV 2 (463 on ART) have been enrolled ([Table 2](#pone-0066135-t002){ref-type="table"}).

10.1371/journal.pone.0066135.t002

###### Socio-demographic, clinical, biological and therapeutic characteristics of HIV-2 and dual seropositive patients. IeDEA-WA-HIV-2 cohort.
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                               HIV-2-infected patients (N = 1021)   Dually seropositive patient (N = 733)         p^1^                p^2^                   
  --------------------------- ------------------------------------ --------------------------------------- ------------------- ------------------- --------- ---------
  **Age (years)**                                                                                                                                            
  Median (IQR)                         42.8 (34.9--49.4)                      45.3 (38.3--51.7)             40.6 (34.4--47.2)   42.4 (37.0--47.3)   \<0.001    0.048
  \<40                                     163 (34.8)                            144 (26.1)                    117 (43.3)          161 (34.8)       \<0.001    0.061
  40--49                                   175 (37.3)                            185 (33.6)                     87 (32.2)          196 (42.3)                
  \> = 50                                  100 (21.3)                            143 (26.0)                     44 (16.3)           63 (13.6)                
  Unknown                                   31 (6.6)                              79 (14.3)                     22 (8.2)            43 (9.3)                 
  **Gender**                                                                                                                                         0.060     0.732
  Male                                     189 (40.2)                            234 (42.5)                    104 (38.5)          224 (48.4)                
  Female                                   279 (59.4)                            313 (56.8)                    162 (60.0)          236 (51.0)                
  Unknown                                   2 (0.4)                                4 (0.7)                       4 (1.5)             3 (0.6)                 
  **WHO/CDC stage**                                                                                                                                  0.001    \<0.001
  WHO I/II or CDC-A                        118 (25.1)                             78 (14.2)                     29 (10.7)           45 (9.7)                 
  WHO III or CDC-B                          45 (9.6)                             246 (44.6)                     57 (21.1)          254 (54.9)                
  WHO IV or CDC-C                           9 (1.9)                               92 (16.7)                      7 (2.6)            83 (17.9)                
  Unknown                                  298 (63.4)                            135 (24.5)                    177 (65.6)           81 (17.5)                
  **CD4 count**                                                                                                                                              
  Median (IQR)                           535(319--820)                          166(83--247)                  282(108--518)       146(55--249)       0.044    \<0.001
  \<200                                    63 (13.4)                             265 (48.1)                     82 (30.4)          235 (50.8)        0.100    \<0.001
  200--349                                 63 (13.4)                             121 (22.0)                     46 (17.0)          125 (27.0)                
  350--499                                 82 (17.5)                              25 (4.5)                      40 (14.8)           15 (3.2)                 
  500--799                                 114 (24.2)                             13 (2.4)                      41 (15.2)           11 (2.4)                 
  \>800                                    117 (24.9)                              3 (0.5)                      19 (7.0)             2 (0.4)                 
  Unknown                                   31 (6.6)                             124 (22.5)                     42 (15.6)           75 (16.2)                
  **ART**                                                                                                                                                    
  Not on ART                                  470                                    --                            270                 --           \<0.001  
  NRTIs+PI                                     --                                463 (84.0)                        --              305 (65.9)                
  NRTIs+NNRTI                                  --                                 39 (7.1)                         --              123 (26.6)                
  3 NRTIs                                      --                                 48 (8.7)                         --               29 (6.3)                 
  Mono/bi-therapy                              --                                  1 (0.2)                         --                6 (1.2)                 
  **Year of enrolment^\$^**                                                                                                                                  
  1992--2003                               62 (13.5)                              51 (9.3)                      88 (33.0)           81 (17.5)       \<0.001   \<0.001
  2004--2005                               121 (26.4)                            126 (22.9)                     89 (33.3)          149 (32.2)                
  2006--2007                               96 (21.0)                             155 (28.1)                     28 (10.5)          100 (21.6)                
  2008--2011                               179 (39.1)                            219 (39.7)                     62 (23.2)          133 (28.7)                

IQR: Interquartile range, ART: antiretroviral treatment.

p^1^: comparison between two group of patient on ART, p^2^ =  comparison between the two groups of patients in care.

PI: protease inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, NNRTI: non nucleoside reverse transcriptase inhibitors.

*\$: 15 missing data for enrolment date in care.*

Among patients whom were ART-naive, the median age was 42.8 years, interquartile range (IQR) (34.9--49.4) for HIV-2 patients and 40.6 years, IQR (34.4--47.2) for dually seropositive patients (p\<0.001). At enrolment, 49.1% of HIV-2 patients had CD4 count ≥500 cells/mm^3^ versus 22.2% for dually seropositive patients (p\<0.001) ([Table 2](#pone-0066135-t002){ref-type="table"}).

At ART initiation, the median age of HIV-2 patients was 45.3 years, IQR (38.3--51.7) and 42.4 years, IQR (37.0--47.3) for dually seropositive patients (p = 0.048). In addition, the proportion of patients aged ≥50 years was twice as high in HIV-2 patients compared with dually seropositive patients (26.0% vs 13.6%, p\<0.001). Of note, 16.7% of HIV-2 patients had an advanced clinical stage (WHO stage IV or CDC-C), a figure comparable to the 17.9% observed among dually seropositive patients.

In all clinical centers, the most commonly used first-line ART regimen was a protease inhibitors (PI) based regimen, which was initiated in 84.0% of HIV-2 patients and 65.9% for dually seropositive patients. The most common PI based regimen prescribed was lopinavir-ritonavir (Aluvia® or Kaletra®) for 36.4% HIV-2 patients and 26.9% for dually seropositive patients on ART. Despite the fact that NNRTIs are not recommended among HIV-2 patients due to intrinsic resistance, it was initiated in 39 (7.1%) of HIV-2 patients and 123 (26.6%) of dually seropositive patients ([Table 2](#pone-0066135-t002){ref-type="table"}). Finally, 3 NRTIs regimens were prescribed for 8.7% of HIV-2 infected patients and for 6.3% of dually seropositive patients. The most prescribed NRTI regimens among HIV-2 infected patients were the followings zidovune+lamivudine (3TC) (63.3%), stavudine (d4T) +3TC (30.5%), tenofovir+(emtricitabine or 3TC) (2.7%) and didanosine+ (abacavir+d4T) (1.1%).

The median CD4 count at the ART initiation is 166 cells/mm^3^, IQR (83--247) among HIV-2 infected patients and 146 cells/mm^3^, IQR (55--249) among dually seropositive patients (p\<0.001). At 24 months on ART, the median CD4 count increased 126 cells/mm^3^ for HIV-2 patients and 169 cells/mm^3^ for dually seropositive patients ([Figure 2](#pone-0066135-g002){ref-type="fig"}). Of 551 HIV-2 patients on ART, 32 (5.8%) died and 56 (10.2%) were considered lost to follow-up during the median time on ART of 2.4 years, IQR (0.7--4.3). Of 463 dually seropositive patients on ART, 21 (4.6%) died and 46 (9.9%) were considered lost to follow-up during a median follow on ART of 2.6 years (0.9--5.5). [Table 3](#pone-0066135-t003){ref-type="table"} summarizes the follow-up characteristics of both ARV-naïve and ARV-treated HIV-2 and dually seropositive patients.

![Median CD4 count (cells/µl) and interquartile range, from ART initiation in the HIV-2 cohort, IeDEA West Africa collaboration.](pone.0066135.g002){#pone-0066135-g002}
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###### Follow-up characteristics. IeDEA-WA-HIV-2 cohort.
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                                                      HIV-2-infected patients   Dually seropositive patient                 
  -------------------------------------------------- ------------------------- ----------------------------- -------------- ----------------
  **Duration**                                                                                                              
  Median in years (IQR)                                    1.1 (0--3.8)               2.4 (0.7--4.3)          0.1 (0--2.0)   2.6 (0.9--5.5)
  \<12 months (%)[\$](#nt107){ref-type="table-fn"}          229 (48.7)                  161 (29.2)             183 (67.8)      126 (27.2)
  12--23 months (%)                                          60 (12.8)                   87 (15.8)              19 (7.0)       73 (15.8)
  24--37 months (%)                                          40 (8.5)                    72 (13.1)              19 (7.0)        45 (9.7)
  \>37 months (%)                                           141 (30.0)                  231 (41.9)             49 (18.2)       219 (47.3)
  **Status (%)**                                               n (%)                       n (%)                 n (%)           n (%)
  Alive                                                     355 (75.5)                  449 (81.5)             190 (70.4)      387 (83.6)
  Deceased                                                    7 (1.5)                    32 (5.8)               10 (3.7)        21 (4.6)
  LTFU[\*](#nt106){ref-type="table-fn"}                      96 (20.4)                   56 (10.2)             69 (25.6)        46 (9.9)
  Dropped out                                                 5 (1.1)                     4 (0.7)                0(0.0)         1 (0.2)
  Transferred -out                                            7 (1.5)                    10 (1.8)               1 (0.3)         8 (1.7)

IQR: Interquartile range, ART: antiretroviral treatment initiated.

Number of patients lost to follow-up reported and recorded in the HIV-2 database.

patients without any follow-up are included.

Discussion {#s4}
==========

The IeDEA-WA-HIV-2 cohort is a multi-centre, multi-country collaboration on HIV-2 and dually seropositive patients in West Africa, the only region of the world where the two viruses are endemic (HIV-2) and epidemic (HIV-1). This is one of the largest datasets in the world on HIV-2 and provides the opportunity to study HIV-2 in resource-limited settings (RLS). The only other large HIV-2 database is the ACHIEV~2~E HIV-2 Collaboration in Europe and North America [@pone.0066135-Benard1]. The IeDEA-WA HIV-2 cohort aims, first, to build and strengthen an operational and clinical research network that describes HIV-2 case management in RLS. Treatment outcomes and their determinants are being investigated by pooling individual patient data, and should thus appropriately inform policies and programmes by examining various models of care, clinical and operational outcomes. The network is reflecting on a similar successful experience of adult treatment centres in lower income countries [@pone.0066135-Egger1] and aims to rapidly bridge the gap in clinical and programmatic information for people living with HIV-2. Furthermore, this collaboration includes not only patients on ART but also patient "in care" but ARV-naive. In addition, we have also implemented an HIV-2 and HIV-1/HIV-2 Drug Resistance Database that will allow us to conduct surveys of genotypic resistance and virological response in the future. Moreover, we are in the process of implementing and standardizing plasma HIV-2 RNA viral load quantification across sites.

It is important to note that several centres identified as possible sites of enrolment and follow-up of HIV-2 patients in the West African region did not participate in this collaboration because they do not perform routinely HIV serologic testing that discriminates HIV-1 from HIV-2, (e.g. Nigeria, which has the largest number of HIV-infected patients in West Africa).

In West Africa, rapid HIV assays are often used for the diagnosis of HIV-1 or HIV-2 or dual HIV-1/HIV-2 infection. This strategy is based on the demonstration of virus-specifics antibodies using enzyme-linked immunosorbent assay based-technique [@pone.0066135-Peterson2], [@pone.0066135-New1], [@pone.0066135-Imai1], [@pone.0066135-Toro1]. In the West African region, current serological tests for the diagnosis of HIV-2 include: 1) For screening purposes: Determine, ELISA and Murex ICEVIH1.0.2., 2) for confirmatory testing and HIV-1, HIV-2 differentiation: Genie II HIV-1/2 (Bio-Rad, Marnes la Coquette, France), Immunocomb HIV 1&2 (Orgenics Ltd, Yavne, Israel), SD Bioline (Standard Diagnostics, Inc., Korea) or HIV-2 and HIV-1 Western blots. 3) Final confirmation is made when available with Pepti-LAV (Bio-Rad), Western Blot, HIV DNA PCR (in house), and/or Inno-LIA HIV I/II (Innogenetics, Belgium) depending on the laboratories. A specific survey on serological testing is ongoing within this collaboration in order to propose soon a common diagnosis algorithm for all the participating centers.

HIV-2 may be underreported because antibody cross-reactivity between HIV-1 and HIV-2 is common and frequently results in misdiagnosis of HIV-2 as HIV-1 or dual infection [@pone.0066135-Rouet1], [@pone.0066135-Torian1]. Therefore screening tests need high sensitivity for HIV-2, while confirmatory testing may require multiple steps in order to reliably distinguish between HIV-1, HIV-2, and HIV-1/HIV-2 dual infection. The consequence of misdiagnosis that results in HIV-2 and dually seropositive patients going on treatment that ignores their HIV-2 as reported here with 7.1% of HIV-2 patients who had initiated NNRTI regimens because the clinician did not know they had HIV-2 at the time of ART initiation. Dual infection can be proven only by the presence of both HIV-1 and HIV-2 DNA or RNA by specific PCR the isolation of both viruses from the same individual [@pone.0066135-Peeters1]. However plasma HIV-2 RNA may be undetectable using current assays, it cannot be used as a diagnostic test. HIV-2 proviral DNA may be low or repeatedly negative in some asymptomatic individuals, making confirmation of diagnosis difficult [@pone.0066135-Damond2].

CD4 count is the most readily available means for monitoring disease progression in HIV-2-infected patients. However, CD4 count often will not increase as rapidly as it generally occurs with successful therapy of HIV-1 mono-infection [@pone.0066135-Drylewicz1], [@pone.0066135-Drylewicz2], [@pone.0066135-Matheron2]. It has been reported that there is less and slower CD4 count recovery in older patients with HIV-1, limiting the CD4 interpretation of CD4 trajectory in older HIV-2 patients on ART [@pone.0066135-Balestre1]. Thus, there is no validated definition of immunological failure in HIV-2 infection. Consequently, in West Africa, it is difficult to manage HIV-2 patients with ART failure since there are no commercially available viral load and resistance tests for HIV-2 infection [@pone.0066135-Damond3]--[@pone.0066135-Chang1], There are indeed very limited 1^st^ and 2^nd^ line treatment options for HIV-2 in most RLS in West Africa. The lack of available second-line HIV-2 therapy options should be considered when choosing first-line ART, as the initial regimen choice, narrows later treatment options. Additionally, in HIV-1/HIV-2 dual infection, clinical management needs to focus on controlling both viruses with agents that are active against both HIV-1 and HIV-2 [@pone.0066135-Peterson2].

Finally our large study of HIV-2 and HIV-1/HIV-2 dual infection in West Africa suggests that routine clinical care is less than optimal and that management and treatment of HIV-2 could be further informed by ongoing studies and randomized clinical trials in this population.
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